---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-010409"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:07:54.062912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DiaMedica reports FY2025 cash $59.9M; ReMEDy2 trial nearing 70% interim enrollment

## Summary
- Cash and investments $59.9M at Dec 31, 2025, up from $44.1M; runway through 2H 2027.
- ReMEDy2 Phase 2/3 AIS trial approaching 70% of required interim enrollment; analysis in 2H 2026.
- R&D expenses $24.6M vs $19.1M YoY driven by ReMEDy2 expansion and PE program costs.
- G&A expenses $9.8M vs $7.6M YoY; net cash used in ops $29.1M vs $22.1M.
- PE Phase 2 IST Part 1a enrollment ongoing; DiaMedica-sponsored Phase 2 to start later 2026.

## SEC filing metadata
- accession: 0001437749-26-010409
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/0001437749-26-010409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/dmtp20260330_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-010409
- JSON: https://secwatch.observer/filing/0001437749-26-010409.json
- Plain text: https://secwatch.observer/filing/0001437749-26-010409.txt

## Key facts
- Earnings Releases
  DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: On March 30, 2026, DiaMedica Therapeutics Inc. (the "Company") announced its consolidated financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/0001437749-26-010409-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.